Pharmacokinetic and Safety Study of Oral Lofexidine in Neonates Experiencing Opioid Withdrawal Due to Intrauterine Exposure to Opioids

Recruiting

Phase 2

Pharmacokinetic and Safety Study of Oral Lofexidine in Neonates Experiencing Opioid Withdrawal Due to Intrauterine Exposure to Opioids

Sponsor:

USWM, LLC (dba US WorldMeds)

Code:

NCT06047834

Conditions

Opioid Withdrawal (Disorder)

Eligibility Criteria

Sex: All

Age: 0 - 6

Healthy Volunteers: Not accepted

Interventions

Standard of Care with Lofexidine

Standard of Care without Lofexidine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by USWM, LLC (dba US WorldMeds) on 2025-05-14.